MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-12-31.

Cash Flow Overview

Free Cash flow
-$92,325K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-110,635 -126,502 -120,613
Stock-based compensation
12,715 13,358 18,510
Depreciation on property and equipment
101 105 107
Non-cash lease expense
25 24 24
Accounts receivable
-319 25 -129
Prepaid expenses and other current assets
-2,869 -1,164 -498
Other assets
38 -167 1,361
Accounts payable
1,563 -1,065 -9,401
Accrued expenses and other current liabilities
756 10,259 -5,304
Net cash used in operating activities
-92,325 -102,515 -117,411
Purchase of property and equipment
0 0 0
Net cash used in investing activities
0 0 0
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions
544,194 --
Payment of offering costs
586 --
Proceeds from stock options exercised
20,995 24,595 2,918
Net cash provided by financing activities
564,603 24,595 2,918
Effect of exchange rate changes on cash and cash equivalents
377 878 -566
Net change in cash and cash equivalents
472,655 -77,042 -115,059
Cash and cash equivalents at beginning of period
521,870 713,971 -
Cash and cash equivalents at end of period
994,525 521,870 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT)